Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man
Laboy-Ortiz, Ián.E.; Velez-Maymí, S.; Hernán Martínez, Jé.; Trinidad, R.; Mangual, M.; Sanchez, A.; Gutierrez, M.; Mansilla, P.; Rivera, C.; Palermo, C.; de Lourdes Miranda, Mía.; Brau, R.
Boletin de la Asociacion Medica de Puerto Rico 108(1): 31-36
2016
ISSN/ISBN: 0004-4849 PMID: 29193928 Document Number: 702783
Prolactinomas are the most common hormone-secreting pituitary tumors
Document emailed within 1 workday
Related Documents
Laboy-Ortiz, I.án.E.; Velez-Maymí, S.; Hernán Martínez, J.é; Trinidad, R.; Mangual, M.; Sanchez, A.; Gutierrez, M.; Mansilla, P.; Rivera, C.; Palermo, C.; Lourdes Miranda, M.ía.; Brau, R. 2016: Secondary Resistance to dopamine agonist after thirteen months of successful treatment Boletin de la Asociacion Medica de Puerto Rico 108(1): 29-34Malmberg; Mikaels; Mohell, N. 1998: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding Journal of Pharmacology and Experimental Therapeutics 285(1): 119-126
Ceccherini-Nelli, A.; Guazzelli, M. 1994: Treatment of refractory OCD with the dopamine agonist bromocriptine Journal of Clinical Psychiatry 55(9): 415-416
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Eijsbouts, A.; van den Hoogen, F.; Laan, R.F.; Hermus, R.M.; Sweep, F.C.; van de Putte, L. 1999: Treatment of rheumatoid arthritis with the dopamine agonist quinagolide Journal of Rheumatology 26(10): 2284-2285
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Kohli, J.D.; Goldberg, L.I.; Volkman, P.H.; Cannon, J.G. 1978: N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist Journal of Pharmacology and Experimental Therapeutics 207(1): 16-22
Hjorth, S.; Jackson, D.; Carlsson, A.; Lindberg, P. 1982: A behavioral study of the changes in the CNS of mice after subchronic treatment with the dopamine autoreceptor agonist 3-PPP Psychopharmacology Bulletin 18(4): 149-152
Fuller, R.W.; Clemens, J.A.; Hynes, M.D. 1982: Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia Journal of Clinical Psychopharmacology 2(6): 371-375
Techasena, W.; Wongwacharapiboon, P.; Terawanich, S.; Pattamadilok, S. 2011: A comparison study of measles antibody between two doses vaccination at 9, 18 months and single dose at 9 months in children 4-6 years old Journal of the Medical Association of Thailand 94(3): 309-315
Piercey, M.F.; Hoffmann, W.E.; Vogelsang, G.D.; Travis, M. 1987: Electrophysiological evaluation of a partial agonist of dopamine receptors Journal of Pharmacology and Experimental Therapeutics 243(1): 391-396
Kilpatrick, G.J.; el Tayar, N.; Van de Waterbeemd, H.; Jenner, P.; Testa, B.; Marsden, C.D. 1986: The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors Molecular Pharmacology 30(3): 226-234
Girdhar, A.; Sharma, D.C.; Sachdev, K.S. 1982: Anorectic effect of SK and F 38393, a new dopamine agonist in rats Indian Journal of Physiology and Pharmacology 26(4): 317-320
Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Wu, J.; Liang, Y.; Nawaz, Z.; Hyder, S.M. 2005: Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance International Journal of Oncology 27(6): 1647-1659
Crouzet, J.; Beraneck, L.; Juan, L.H. 1992: Alcaptonuric rheumatism. a case followed for thirteen years Revue du Rhumatisme et des Maladies Osteo-Articulaires 59(4): 298-300
Andersen, A.N. 1977: Bromocriptine (Parlodel). a prolactin inhibiting dopamine receptor agonist Ugeskrift for Laeger 139(22): 1311-1313
Arnerić, S.P.; Long, J.P.; Williams, M.; Goodale, D.B.; Mott, J.; Lakoski, J.M.; Gebhart, G.F. 1983: RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 224(1): 161-170
Trugman, J.M.; Arnold, W.S.; Touchet, N.; Wooten, G.F. 1989: D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography Journal of Pharmacology and Experimental Therapeutics 250(3): 1156-1160
Fernández De Cevallos-Urueta, J.; Aguilar-Guzmán, M.L.; Olivares-González, M. 1988: Comparative analysis immediately after treatment and 2 years and 10 months after treatment by posterior-anterior traction of the maxilla in patients with cleft lip and palate using a facial mask Boletin Medico del Hospital Infantil de Mexico 45(12): 837-845